These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37949730)

  • 41. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.
    Boike TP; Lotan Y; Cho LC; Brindle J; DeRose P; Xie XJ; Yan J; Foster R; Pistenmaa D; Perkins A; Cooley S; Timmerman R
    J Clin Oncol; 2011 May; 29(15):2020-6. PubMed ID: 21464418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
    Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
    Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Multicenter Phase 2 Study of Ultrahypofractionated Stereotactic Boost After External Beam Radiotherapy in Intermediate-risk Prostate Carcinoma: A Very Long-term Analysis of the CKNO-PRO Trial.
    Pasquier D; Nickers P; Peiffert D; Maingon P; Pommier P; Lacornerie T; Tresch E; Barthoulot M; Lartigau E
    Eur Urol Open Sci; 2023 Aug; 54():80-87. PubMed ID: 37545850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
    Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
    Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT.
    Fuller D; Wurzer J; Shirazi R; Bridge S; Law J; Crabtree T; Mardirossian G
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):291-299. PubMed ID: 31629838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
    Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
    BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer.
    Bergamin S; Eade T; Kneebone A; Booth J; Hsiao E; Schembri GP; Szymura K; Le A; Kwong C; Brown C; Hunter J; Hruby G
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1172-1178. PubMed ID: 32659332
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
    Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
    Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
    Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
    Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
    Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking: A Phase II Study.
    D'Agostino GR; Mancosu P; Di Brina L; Franzese C; Pasini L; Iftode C; Comito T; De Rose F; Guazzoni GF; Scorsetti M
    Am J Clin Oncol; 2020 Sep; 43(9):628-635. PubMed ID: 32889832
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
    King CR; Brooks JD; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):877-82. PubMed ID: 21300474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
    Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.
    Patel KR; Rydzewski NR; Schott E; Cooley-Zgela T; Ning H; Cheng J; Salerno K; Huang EP; Pinto PA; Lindenberg L; Mena E; Choyke P; Turkbey B; Citrin DE
    Pract Radiat Oncol; 2023; 13(6):540-550. PubMed ID: 37442430
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SABR for High-Risk Prostate Cancer: A Prospective Multilevel MRI-Based Dose Escalation Trial.
    Hannan R; Salamekh S; Desai NB; Garant A; Folkert MR; Costa DN; Mannala S; Ahn C; Mohamad O; Laine A; Kim DWN; Dickinson T; Raj GV; Shah RB; Wang J; Jia X; Choy H; Roehrborn CG; Lotan Y; Timmerman RD
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):290-301. PubMed ID: 34774676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: a dose-escalation trial (DESTROY-4).
    Deodato F; Ferro M; Bonome P; Pezzulla D; Romano C; Buwenge M; Cilla S; Morganti AG; Macchia G
    Strahlenther Onkol; 2024 Mar; 200(3):239-249. PubMed ID: 38180492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.